| Title: | The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma |
| Authors: | Yamaguchi, Shigeru Browse this author |
| Ishi, Yukitomo Browse this author |
| Motegi, Hiroaki Browse this author |
| Okamoto, Michinari Browse this author |
| Kobayashi, Hiroyuki Browse this author |
| Hirata, Kenji Browse this author |
| Oda, Yoshitaka Browse this author |
| Tanaka, Shinya Browse this author |
| Terasaka, Shunsuke Browse this author |
| Houkin, Kiyohiro Browse this author |
| Keywords: | Astrocytoma |
| Bevacizumab |
| Glioblastoma |
| Radiotherapy |
| Temozolomide |
| Issue Date: | Dec-2020 |
| Publisher: | Edizioni Minerva Medica |
| Journal Title: | Journal of Neurosurgical Sciences |
| Volume: | 64 |
| Issue: | 6 |
| Start Page: | 502 |
| End Page: | 508 |
| Publisher DOI: | 10.23736/S0390-5616.18.04463-6 |
| Abstract: | BACKGROUND: Although newly diagnosed high-grade glioma patients in Japan can receive bevacizumab (BEV) as first-line chemotherapy. randomized clinical trials have not shown a survival benefit for BEV for these patients. In this study, we investigated whether selective add-on BEV for patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA) improves prognosis, in cases where tumors were continuously growing during radiotherapy concomitant with temozolomide (TMZ). METHODS: We conducted a retrospective survey of the overall survival (OS) of patients with GBM;AAs who were treated in our institution between 2006 and 2016. Patients whose tumors were continuously growing regardless of radiotherapy were categorized as the "progressive" group; remaining patients were categorized as the "non-progressive" group. Since 2013, patients in the "progressive" group received add-on BEV therapy with the Stupp regimen during or just after radiotherapy. RESULTS: Of 151 GBM/AA patients, 34 (22.5%) were categorized in the "progressive" group. Median OSs of the "progressive" and "nonprogressive" groups were 13.2 months and 25.3 months, respectively (P<0.001). Twelve patients in the "progressive" group received add-on BEV therapy, and their median OS was 20.2 months; whereas for the remaining 22 patients in the "progressive" group who were treated before the BEV era, their median OS was 10.5 months. In the "progressive" group, add-on BEV significantly extended OS (P 0.018) and was the lone clinical factor of better prognosis. CONCLUSIONS: We found that, for patients with GBM/AAs whose tumors were continuously growing during radiotherapy, add-on BEV treatment resulted in survival benefits. |
| Rights: | This is a postprint version of the article published in Journal of Neurosurgical Sciences. This version is free to view and download to private research and study only. Not for redistribution or re-use. ©Edizioni Minerva Medica. The final published article is available online on Minerva Medica website at https:doi.org 10.23736/S0390-5616.18.04463-6. |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/83410 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
